11 DECEMBER 2006
FGFR1 as a potential therapeutic target for lobular breast carcinomas
Breakthrough scientists have identified FGFR1 as a potential therapeutic target, for lobular breast carcinomas.
Using chromosomal and microarray-based CGH analysis of classic lobular carcinomas of the breast, the scientists revealed a subgroup that harbours co-amplification of FGFR1 and CCND1 and expresses these oncogenes at high levels. The cell line MDA-MB-134, which has all the hallmark molecular features of classic lobular carcinoma (i.e. positivity for hormone receptors, lack of HER2 and E-cadherin expression, 16q-), was shown to harbour FGFR1 and CCND1 co-amplification and express high levels of FGFR1 mRNA. When transfected with siRNA against FGFR1 or treated with SU5402, a FGFR1 tyrosine kinase inhibitor, the growth of MDA-MB-134 cells was significantly inhibited. Our findings suggest that FGFR1 may be useful as a therapeutic target for this subgroup of breast cancers.
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Reis-Filho et al. Clin Cancer Res. 2006 12(22):6652-62.
Using chromosomal and microarray-based CGH analysis of classic lobular carcinomas of the breast, the scientists revealed a subgroup that harbours co-amplification of FGFR1 and CCND1 and expresses these oncogenes at high levels. The cell line MDA-MB-134, which has all the hallmark molecular features of classic lobular carcinoma (i.e. positivity for hormone receptors, lack of HER2 and E-cadherin expression, 16q-), was shown to harbour FGFR1 and CCND1 co-amplification and express high levels of FGFR1 mRNA. When transfected with siRNA against FGFR1 or treated with SU5402, a FGFR1 tyrosine kinase inhibitor, the growth of MDA-MB-134 cells was significantly inhibited. Our findings suggest that FGFR1 may be useful as a therapeutic target for this subgroup of breast cancers.
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Reis-Filho et al. Clin Cancer Res. 2006 12(22):6652-62.
